Biomica Announces Encouraging Initial Findings From Phase 1 Clinical Trial Of BMC128, Its Microbiome-Based Immuno-Oncology Candidate, In Combination With Nivolumab For Patients With NSCLC, Melanoma, Or RCC
Portfolio Pulse from Benzinga Newsdesk
Biomica has announced promising initial results from its Phase 1 clinical trial of BMC128, a microbiome-based immuno-oncology candidate, in combination with Nivolumab for patients with NSCLC, melanoma, or RCC.
May 23, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomica, a subsidiary of Evogene Ltd. (EVGN), has announced promising initial results from its Phase 1 clinical trial of BMC128, a microbiome-based immuno-oncology candidate, in combination with Nivolumab for patients with NSCLC, melanoma, or RCC.
The positive initial findings from the Phase 1 trial of BMC128 could boost investor confidence in Evogene (EVGN), as it indicates potential progress in their immuno-oncology pipeline. This news is likely to have a positive short-term impact on EVGN's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80